吉利德科学公司近日公布2025年第二季度财务数据,除去抗病毒药物瑞德西韦的销售额,公司其他产品销售额同比增长4%。数据显示,瑞德西韦在本季度的销售额同比下降,但公司其他主要产品线表现出稳定增长。吉利德科学表示,这一增长主要得益于其在肿瘤学、免疫学和抗病毒治疗领域的核心产品持续获得市场认可。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.